258 related articles for article (PubMed ID: 28477733)
41. A paradoxical gender dissociation within the growth hormone/insulin-like growth factor I axis during protracted critical illness.
Van den Berghe G; Baxter RC; Weekers F; Wouters P; Bowers CY; Veldhuis JD
J Clin Endocrinol Metab; 2000 Jan; 85(1):183-92. PubMed ID: 10634385
[TBL] [Abstract][Full Text] [Related]
42. Hypopituitarism in five PROP1 mutation siblings: long-lasting natural course and the effects of growth hormone replacement introduction in middle adulthood.
Doknic M; Gasic V; Stojanovic M; Pavlovic S; Marinkovic S; Miljic D; Pekic S; Manojlovic-Gacic E; Damjanovic D; Soldatovic I; Petakov M
Pituitary; 2020 Aug; 23(4):400-408. PubMed ID: 32415500
[TBL] [Abstract][Full Text] [Related]
43. Interrelations between growth hormone and sex hormones: physiology and therapeutic consequences.
Zachmann M
Horm Res; 1992; 38 Suppl 1():1-8. PubMed ID: 1295806
[TBL] [Abstract][Full Text] [Related]
44. Modulation of cortisol metabolism by low-dose growth hormone replacement in elderly hypopituitary patients.
Toogood AA; Taylor NF; Shalet SM; Monson JP
J Clin Endocrinol Metab; 2000 Apr; 85(4):1727-30. PubMed ID: 10770221
[TBL] [Abstract][Full Text] [Related]
45. Effects of raloxifene and estrogen on bioactive IGF1 in GH-deficient women.
Birzniece V; Magnusson NE; Ho KK; Frystyk J
Eur J Endocrinol; 2014 Mar; 170(3):375-83. PubMed ID: 24347426
[TBL] [Abstract][Full Text] [Related]
46. Paracrine regulation of growth hormone secretion by estrogen in women.
Birzniece V; Sata A; Sutanto S; Ho KK
J Clin Endocrinol Metab; 2010 Aug; 95(8):3771-6. PubMed ID: 20444909
[TBL] [Abstract][Full Text] [Related]
47. Comparison of tamoxifen and testosterone propionate in male rats: differential prevention of orchidectomy effects on sex organs, bone mass, growth, and the growth hormone-IGF-I axis.
Fitts JM; Klein RM; Powers CA
J Androl; 2004; 25(4):523-34. PubMed ID: 15223841
[TBL] [Abstract][Full Text] [Related]
48. Ten-year GH replacement increases bone mineral density in hypopituitary patients with adult onset GH deficiency.
Götherström G; Bengtsson BA; Bosaeus I; Johannsson G; Svensson J
Eur J Endocrinol; 2007 Jan; 156(1):55-64. PubMed ID: 17218726
[TBL] [Abstract][Full Text] [Related]
49. The growth hormone (GH)-insulin-like growth factor axis during testosterone replacement therapy in GH-treated hypopituitary males.
Fisker S; Nørrelund H; Juul A; Skakkebaek NE; Christiansen JS; Jørgensen JO
Growth Horm IGF Res; 2001 Apr; 11(2):104-9. PubMed ID: 11472076
[TBL] [Abstract][Full Text] [Related]
50. GH replacement in adults: interactions with other pituitary hormone deficiencies and replacement therapies.
Filipsson H; Johannsson G
Eur J Endocrinol; 2009 Nov; 161 Suppl 1():S85-95. PubMed ID: 19684055
[TBL] [Abstract][Full Text] [Related]
51. Body composition and physical fitness are major determinants of the growth hormone-insulin-like growth factor axis aberrations in adult Turner's syndrome, with important modulations by treatment with 17 beta-estradiol.
Gravholt CH; Naeraa RW; Fisker S; Christiansen JS
J Clin Endocrinol Metab; 1997 Aug; 82(8):2570-7. PubMed ID: 9253336
[TBL] [Abstract][Full Text] [Related]
52. Estrogen and tamoxifen interplay with T(3) in male rats: pharmacologically distinct classes of estrogen responses affecting growth, bone, and lipid metabolism, and their relation to serum GH and IGF-I.
Fitts JM; Klein RM; Powers CA
Endocrinology; 2001 Oct; 142(10):4223-35. PubMed ID: 11564678
[TBL] [Abstract][Full Text] [Related]
53. Biochemical and biophysical markers of endothelial dysfunction in adults with hypopituitarism and severe GH deficiency.
Elhadd TA; Abdu TA; Oxtoby J; Kennedy G; McLaren M; Neary R; Belch JJ; Clayton RN
J Clin Endocrinol Metab; 2001 Sep; 86(9):4223-32. PubMed ID: 11549653
[TBL] [Abstract][Full Text] [Related]
54. Dehydroepiandrosterone (DHEA) replacement reduces growth hormone (GH) dose requirement in female hypopituitary patients on GH replacement.
Brooke AM; Kalingag LA; Miraki-Moud F; Camacho-Hübner C; Maher KT; Walker DM; Hinson JP; Monson JP
Clin Endocrinol (Oxf); 2006 Nov; 65(5):673-80. PubMed ID: 17054472
[TBL] [Abstract][Full Text] [Related]
55. The effects of treatment and the individual responsiveness to growth hormone (GH) replacement therapy in 665 GH-deficient adults. KIMS Study Group and the KIMS International Board.
Bengtsson BA; Abs R; Bennmarker H; Monson JP; Feldt-Rasmussen U; Hernberg-Stahl E; Westberg B; Wilton P; Wüster C
J Clin Endocrinol Metab; 1999 Nov; 84(11):3929-35. PubMed ID: 10566630
[TBL] [Abstract][Full Text] [Related]
56. Increased disorderliness and decreased mass and daily rate of endogenous growth hormone secretion in adult Turner syndrome: the impact of body composition, maximal oxygen uptake and treatment with sex hormones.
Gravholt CH; Veldhuis JD; Christiansen JS
Growth Horm IGF Res; 1998 Aug; 8(4):289-98. PubMed ID: 10984320
[TBL] [Abstract][Full Text] [Related]
57. Effects of GH and/or sex steroids on circulating IGF-I and IGFBPs in healthy, aged women and men.
Münzer T; Rosen CJ; Harman SM; Pabst KM; St Clair C; Sorkin JD; Blackman MR
Am J Physiol Endocrinol Metab; 2006 May; 290(5):E1006-13. PubMed ID: 16390864
[TBL] [Abstract][Full Text] [Related]
58. Differential effects of androgens and estrogens over cellular GH sensitivity in HEPG2 cells.
Ocaranza P; Íñiguez G; Johnson MC; Cassorla F
Growth Horm IGF Res; 2021; 57-58():101390. PubMed ID: 33975196
[TBL] [Abstract][Full Text] [Related]
59. The effect of growth hormone substitution on cognitive performance in adult patients with hypopituitarism.
Oertel H; Schneider HJ; Stalla GK; Holsboer F; Zihl J
Psychoneuroendocrinology; 2004 Aug; 29(7):839-50. PubMed ID: 15177699
[TBL] [Abstract][Full Text] [Related]
60. Effects of the selective estrogen receptor modulator, raloxifene, on the somatotropic axis and insulin-glucose homeostasis.
Oleksik AM; Duong T; Pliester N; Asma G; Popp-Snijders C; Lips P
J Clin Endocrinol Metab; 2001 Jun; 86(6):2763-8. PubMed ID: 11397884
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
